Products will only be used for legitimate research purposes
The first study, conducted in male mice, found that exenatide treatment did not significantly alter morphine-conditioned place preference, intravenous self-administration of the short-acting synthetic opioid remifentanil, morphine-induced locomotor activity, or the somatic signs of morphine withdrawal.163 Additionally, exenatide did not significantly affect the analgesic efficacy of morphine in the hot-plate test.163 Notably, remifentanil self-administration was comparable to or increased in mice lacking central nervous system GLP-1 receptors relative to wild-type controls.163 It is important to acknowledge that the association between GLP-1RAs and suicidal behavior has not been sufficiently studied
10.1016/j.endmts.2024.100159 Endocr Metab Sci
The GLP-1 and breastfeeding guide covers the nuances of this topic, but the general recommendation is to stop GLP-1 treatment at least 2 months before attempting conception due to the long half-life
For patients with prediabetes or insulin resistance driving weight gain and metabolic dysfunction, semaglutide addresses the glycemic component while producing weight loss that further improves insulin sensitivity a compounding metabolic benefit
The quality of results and the minimal side effects make it ideal for health-conscious users who want to optimize their Retatrutide outcomes without taking on significant risk
